Ironwood Pharmaceuticals, Inc.
IRWD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.00 | -2.06 |
| FCF Yield | 0.00% | -12.99% | 8.42% | 2.15% |
| EV / EBITDA | 3.78 | 13.40 | -26.23 | 36.07 |
| Quality | ||||
| ROIC | 67.92% | 8.94% | -10.51% | 0.94% |
| Gross Margin | 0.00% | 99.45% | 98.84% | 100.00% |
| Cash Conversion Ratio | 1.19 | -0.64 | -0.53 | 4.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.79% | -10.29% | -8.68% | -5.06% |
| Free Cash Flow Growth | 100.00% | -175.64% | 30.95% | 54.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 10.91 | -17.70 | 15.12 |
| Interest Coverage | 8.95 | 5.42 | -3.61 | 3.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 88.75 | -176.70 | -1,007.85 | 78.95 |